08/02/2018 | Press release | Distributed by Public on 08/02/2018 08:33
Reference is made to the Private Placement announced 19 June 2018. The share capital increase related to the PP has now been registered with the Norwegian Register of Business Enterprises. The share capital has been increased with NOK 54,736,772 through issuance of 54,736,772 new shares.
The new share capital is thus NOK 288,236,531 divided by 288,236,531 shares, each with a par value of NOK 1.
The new shares have been temporarily issued on a separate ISIN and will be tradable on Oslo Axess as soon as possible after a listing prospectus has been approved by the Norwegian Financial Supervisory Authority on or about 27 August 2018.
Jon Olav Ødegård, CFO of Hofseth BioCare ASA
Phone: +47 936 32 966
E-mail: [email protected]
About Hofseth BioCare ASA:
HBC is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, HBC is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBC's objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.
Hofseth BioCare's headquarters are located in Ålesund, Norway with branches in Oslo, Chicago, Mumbai and Tokyo. HBC is listed on Oslo Stock Exchange Axess list with ticker 'HBC'. More information about Hofseth BioCare at www.hofsethbiocare.com and www.facebook.com/hofsethbiocare
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.